The study will be conducted using an eFlow Electronic Nebulizer optimized for delivery of Kamada’s Alpha-1 Antitrypsin (AAT) product. Kamada’s inhaled AAT has been designated an orphan drug for the treatment of CF and AAT Deficiency, in both Europe and the US.
David Tsur, CEO of Kamada, said: “We believe that, pending the successful completion of the trials and registration process, this formulation will both considerably improve the quality of life and extend the life expectancy of a wide range of Bronchiectasis patients.”